Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia.

American journal of hematology - 1 Aug 2024

Guglielmelli Paola, Mora Barbara, Gesullo Francesca, Mannelli Francesco, Loscocco Giuseppe Gaetano, Signori Leonardo, Pessina Chiara, Colugnat Ilaria, Aquila Raffaela, Balliu Manjola, Maccari Chiara, Romagnoli Simone, Paoli Chiara, Nacca Elena, Fagiolo Lorenzo, Maffioli Margherita, Barbui Tiziano, Passamonti Francesco, Vannucchi Alessandro M

Abstract excerpt

The variant allele frequency (VAF) of driver mutations (JAK2, CALR) in myeloproliferative neoplasms is associated with features of advanced disease and complications. Ruxolitinib and interferon were reported to variably reduce the mutant VAF, but the long-term impact of molecular responses (MR) remains debated. We prospectively measured changes in JAK2 and CALR VAF in 77 patients with polycythemia vera and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calreticulin
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nitriles

Share to Polycythemia Vera

Share to Pyrazoles

Share to Pyrimidines

Share to Thrombocythemia, Essential

Share to Treatment Outcome

Source

Identifiers

PMID: 38841874
DOI: 10.1002/ajh.27400

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia.PMID 38841874Read ↗

The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.Semantic proximity Read ↗

Emerging Significance and Implications of a Durable Complete Molecular Remission in the Treatment of Polycythemia Vera.Semantic proximity Read ↗

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.Semantic proximity Read ↗

The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea.Semantic proximity Read ↗

JAK2 V617F allele burden in polycythemia vera: burden of proof.Semantic proximity Read ↗

The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.Semantic proximity Read ↗

The Mutational Landscape in Polycythemia Vera: Phenotype, Genotype, and Prognostic Correlates.Semantic proximity Read ↗

Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.Semantic proximity Read ↗

Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.Semantic proximity Read ↗

Features and Allele Frequency of JAK2 Exon 12-Mutated Polycythemia Vera in Comparison with JAK2V617F-Mutated Disease.Semantic proximity Read ↗

Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients.Semantic proximity Read ↗

Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.